항체 수탁제조 시장(제3판) : 제조 항체 유형별, 제품 유형별, 사용 발현 시스템 유형별, 사업 규모별, 치료 영역별, 기업 규모별 및 지역별 - 동향과 예측(-2035년)

Antibody Contract Manufacturing Market: Overview

As per Roots Analysis, the global antibody contract manufacturing market is estimated to grow from USD 21.2 billion in the current year to USD 49.1 billion by 2035, at a CAGR of 9.7% during the forecast period, till 2035.

Antibody Contract Manufacturing Market: Growth and Trends

Antibodies, or immunoglobulins, are specialized proteins produced by the immune system to identify and neutralize foreign entities, including pathogens, toxins, and abnormal cells. They are integral to adaptive immunity, binding specifically to antigens and enabling their clearance through targeted immune responses.

Over time, advancements in scientific understanding and bioprocessing technologies have driven significant innovation in the development and manufacturing of increasingly complex and efficacious antibody-based therapeutics. However, these modalities are characterized by high development costs and complex manufacturing requirements, prompting many developers to outsource production to contract manufacturing organizations (CMOs) to address growing industry demand.

CMOs offer access to advanced manufacturing infrastructure, technical expertise, and scalable production capabilities, thereby accelerating development timelines and optimizing operational efficiency. Furthermore, their robust regulatory expertise and quality management systems ensure compliance with global standards, enabling companies to mitigate manufacturing risks and expedite the commercialization of antibody-based therapies.

Growth Drivers: Strategic Enablers of Market Expansion

The antibody contract manufacturing market is witnessing robust growth, driven by continuous advancements in technology and shifting industry strategies. Ongoing innovations in bioprocessing such as the adoption of single-use systems, high-throughput screening platforms, and recombinant DNA technologies have significantly enhanced the efficiency, scalability, and quality of antibody production. These capabilities enable contract manufacturing organizations (CMOs) to deliver cost-effective and flexible solutions, aligning with the evolving demands of complex biologics and biosimilars pipelines.

Further, biopharmaceutical companies are increasingly outsourcing manufacturing operations to CMOs to optimize costs, streamline timelines, and maintain focus on core research and development activities. This growing reliance on specialized partners, coupled with the inherent complexity of antibody production, is reinforcing the strategic importance of CMOs and unlocking new growth opportunities across the market.

Market Challenges: Critical Barriers Impeding Progress

The antibody contract manufacturing market faces several structural and operational challenges that may constrain its growth trajectory. A key concern is the high complexity of antibody production, which demands advanced infrastructure, stringent process control, and specialized technical expertise, often leading to capacity bottlenecks and increased production timelines.

Additionally, evolving and stringent regulatory requirements across regions create compliance burdens for CMOs, necessitating continuous investments in quality systems and validation processes. The market is further challenged by supply chain vulnerabilities, particularly in sourcing critical raw materials and maintaining cold chain logistics. Pricing pressures and intense competition among CMOs also impact profit margins, while concerns around intellectual property protection and technology transfer risks may limit outsourcing decisions by biopharmaceutical companies. Collectively, these factors present significant hurdles for sustained scalability and operational efficiency within the market.

Antibody Contract Manufacturing Market: Key Insights

The report delves into the current state of the antibody contract manufacturing market and identifies potential growth opportunities within industry. Some key findings from the report include:

• With advancements in technology, CMOs leverage innovative tools and methods to revolutionize antibody production, enabling faster and more efficient processes that deliver higher-quality products.
• The biopharma industry is increasingly adopting antibody contract manufacturing to enhance flexibility, minimize contamination risks, and improve cost efficiency.
• Presently, over 140 service providers are engaged in the manufacturing of various types of antibodies across different scales of operation.

• Close to 95% of the manufactures are operating at clinical scale; of these, majority of the manufacturers are utilizing mammalian expression systems for antibody manufacturing.
• Various companies across the globe have actively entered into partnerships with industry and non-industry players in order to provide antibody contract manufacturing services.
• Majority of the agreements inked in this domain were instances of acquisition; of these, most of the deals were inked in the last few years.
• Majority (31%) of the expansions signed in this domain were focused on capability expansions; 38% of these were signed in a particular quarter.
• 75% of the capability expansions were for manufacturing facilities located in North America; however, in Europe, majority (50%) of the expansion initiatives were undertaken for capacity expansions.
• The global installed antibody contract manufacturing capacity is spread across various regions; 37% of this capacity is available in manufacturing facilities based in Asia-Pacific.
• The overall demand is primarily driven by antibodies manufactured by in-house manufactures; majority of the current manufacturing demand is likely to be generated by the antibodies commercialized in North America.

• The antibody manufacturing market is likely to grow at a CAGR of 9.7%, till 2035; presently, majority of the market share is occupied by monoclonal antibodies.

Antibody Contract Manufacturing Market

The market sizing and opportunity analysis has been segmented across the following parameters:

Type of Antibody Manufactured

• Monoclonal
• Bispecific

By Type of Product

• APIs
• FDFs

By Scale of Operation

• Clinical Scale
• Commercial Scale

By Type of Expression System Used

• Mammalian Expression Systems
• Microbial Expression Systems

By Therapeutic Area

• Oncological Disorders
• Cardiovascular Disorders
• Metabolic Disorders
• Infectious Diseases
• Autoimmune Disorders
• Neurological Disorders
• Genetic Disorders
• Other Disorders

By Company Size

• Small Companies
• Mid-sized Companies
• Large and Very Large Companies

Geographical Regions

• North America
• US
• Canada
• Puerto Rico
• Europe
• Germany
• UK
• France
• Spain
• Italy
• Rest of Europe
• Asia-Pacific
• China
• South Korea
• Japan
• Singapore
• Rest of the Asia-Pacific
• Rest of the World
• Israel
• Argentina
• Africa

Antibody Contract Manufacturing Market: Key Segments

Monoclonal Antibodies Occupy the Largest Share of the Global Antibody Contract Manufacturing Market

In terms of the type of antibody manufactured, the market is distributed across monoclonal and bispecific antibody. At present, the monoclonal antibody segment constitutes the majority share of the global antibody contract manufacturing market. However, players are also intensely focused on the development of bispecific antibodies for therapeutic purposes.

By Type of Expression System Used, Microbial Expression System is the Fastest Growing Segment of the Global Antibody Contract Manufacturing Market

In terms of the type of expression system used, the market is distributed across mammalian and microbial expression systems. Currently, the mammalian expression systems capture the highest share of the global antibody contract manufacturing market. This is due to the fact that mammalian expression systems enable antibodies to achieve greater biological activity and binding affinity.

By Scale of Operation, Commercial Scale Segment Occupies the Largest Share of the Global Antibody Contract Manufacturing Market

In terms of the scale of operation, the market is distributed across clinical and commercial scale. In the current year, majority of the antibody contract manufacturing market is held by commercial scale owing to the increasing demand for commercial production of antibodies.

North America Accounts for the Largest Share of the Market

In terms of key geographical regions, the market is distributed across North America, Europe, Asia, Latin America and Middle East and North Africa. North America dominates the antibody contract manufacturing market and accounts for the largest revenue share in the current year. Further, the market in Asia is likely to grow at a higher CAGR in the coming future.

Example Players in the Antibody Contract Manufacturing Market

• AGC Biologics
• Aldevron
• Emergent BioSolutions
• Eurofins CDMO
• FUJIFILM Diosynth Biotechnologies
• KBI Biopharma
• Lonza
• Nitto Avecia Pharma Services
• Novasep
• Pierre Fabre
• Samsung BioLogics
• Synthon
• Thermo Fisher Scientific

Primary Research Overview

Discussions with multiple stakeholders in this domain influenced the opinions and insights presented in this study. The antibody contract manufacturing market report includes detailed transcripts of interviews conducted with the following individuals:

• Managing Director, Mid-sized Company, Austria
• Vice President Business Development, Mid-sized Company, Germany
• Director of Business Development, Mid-sized Company, Poland
• Business Development and Marketing Manager, Mid-sized Company, Spain
• Former Business Development Manager, Mid-sized Company, Taiwan
• Former Communications Manager, Mid-sized Company, Netherlands

Antibody Contract Manufacturing Market: Research Coverage

• Market Sizing and Opportunity Analysis: The report features a thorough analysis of the global antibody contract manufacturing market, in terms of the key market segments, including [A] type of antibody manufactured, [B] type of product, [C] type of expression system used, [D] scale of operation, [E] therapeutic area,
• Market Landscape: An in-depth assessment of the companies involved in antibody contract manufacturing market, based on several relevant parameters, such as [A] year of establishment, [B] company size, [C] location of headquarters, [D] location of manufacturing facilities, [E] scale of operation, [F] type of antibody manufactured, [G] type of expression systems used, and [H] fill / finish operations.
• Company Competitiveness Analysis: A comprehensive competitive analysis of antibody contract manufacturers, examining factors, such as [A] company strength and [B] portfolio strength and [C] portfolio diversity.
• Company Profiles: Detailed profiles of key service providers engaged in the antibody contract manufacturing market, emphasizing on [A] overview of the company, [B] financial information (if available), [C] service portfolio, and [D] recent developments and an informed future outlook.
• Case Study: A detailed comparison of the key features of large and small molecule drugs, along with insights into the manufacturing steps and challenges faced during these manufacturing processes.
• Benchmark Analysis: A detailed benchmark analysis of the key focus areas of small, mid-sized, large and very large companies by comparing their existing capabilities within and outside their respective peer groups.
• Capacity Analysis: An insightful analysis of the overall, installed capacity for manufacturing antibodies, based on various parameters, such as [A] company size and [B] key geographical regions.
• Demand Analysis: An in-depth review of the annual commercial and clinical demand for antibodies, based on various relevant parameters, such as [A] target patient population, [B] dosing frequency and [C] dose strength.
• SWOT Analysis: An analysis of industry affiliated trends, opportunities and challenges, which are likely to impact the evolution of antibody contract manufacturing market.

Key Questions Answered in this Report

• Which are the leading companies in the antibody contract manufacturing market?
• Which region dominates the antibody contract manufacturing market?
• What are the key trends observed in the antibody contract manufacturing market?
• What factors are likely to influence the evolution of this market?
• What are the primary challenges faced by antibody contract manufacturers?
• What is the current and future market size?
• What is the CAGR of this market?
• How is the current and future market opportunity likely to be distributed across key market segments?

Reasons to Buy this Report

• The report provides a comprehensive market analysis, offering detailed revenue projections of the overall market and its specific sub-segments. This information is valuable to both established market leaders and emerging entrants.
• The report offers stakeholders a comprehensive overview of the market, including key drivers, barriers, opportunities, and challenges. This information empowers stakeholders to stay abreast of market trends and make data-driven decisions to capitalize on growth prospects.
• The report can aid businesses in identifying future opportunities in any sector. It also helps in understanding if those opportunities are worth pursuing.
• The report helps in identifying customer demand by understanding the needs, preferences, and behavior of the target audience in order to tailor products or services effectively.
• The report equips new entrants with requisite information regarding a particular market to help them build successful business strategies.
• The report allows for more effective communication with the audience and in building strong business relations.

Additional Benefits

• Complimentary PPT Insights Packs
• Complimentary Excel Data Packs for all Analytical Modules in the Report
• 15% Free Content Customization
• Detailed Report Walkthrough Session with Research Team
• Free Updated report if the report is 6-12 months old or older

TABLE OF CONTENTS

1. PREFACE

• 1.1. Introduction
• 1.2. Market Share Insights
• 1.3. Key Market Insights
• 1.4. Report Coverage
• 1.5. Key Questions Answered

2. RESEARCH METHODOLOGY

• 2.1. Chapter Overview
• 2.2. Research Assumptions
  • 2.2.1. Market Landscape and Market Trends
  • 2.2.2. Market Forecast and Opportunity Analysis
  • 2.2.3. Comparative Analysis
• 2.3. Database Building
  • 2.3.1. Data Collection
  • 2.3.2. Data Validation
  • 2.3.3. Data Analysis
• 2.4. Project Methodology
  • 2.4.1. Secondary Research
    • 2.4.1.1. Annual Reports
    • 2.4.1.2. Academic Research Papers
    • 2.4.1.3. Company Websites
    • 2.4.1.4. Investor Presentations
    • 2.4.1.5. Regulatory Filings
    • 2.4.1.6. White Papers
    • 2.4.1.7. Industry Publications
    • 2.4.1.8. Conferences and Seminars
    • 2.4.1.9. Government Portals
    • 2.4.1.10. Media and Press Releases
    • 2.4.1.11. Newsletters
    • 2.4.1.12. Industry Databases
    • 2.4.1.13. Roots Proprietary Databases
    • 2.4.1.14. Paid Databases and Sources
    • 2.4.1.15. Social Media Portals
    • 2.4.1.16. Other Secondary Sources
  • 2.4.2. Primary Research
    • 2.4.2.1. Types of Primary Research
      • 2.4.2.1.1. Qualitative Research
      • 2.4.2.1.2. Quantitative Research
      • 2.4.2.1.3. Hybrid Approach
    • 2.4.2.2. Advantages of Primary Research
    • 2.4.2.3. Techniques for Primary Research
      • 2.4.2.3.1. Interviews
      • 2.4.2.3.2. Surveys
      • 2.4.2.3.3. Focus Groups
      • 2.4.2.3.4. Observational Research
      • 2.4.2.3.5. Social Media Interactions
    • 2.4.2.4. Key Opinion Leaders Considered in Primary Research
      • 2.4.2.4.1. Company Executives (CXOs)
      • 2.4.2.4.2. Board of Directors
      • 2.4.2.4.3. Company Presidents and Vice Presidents
      • 2.4.2.4.4. Research and Development Heads
      • 2.4.2.4.5. Technical Experts
      • 2.4.2.4.6. Subject Matter Experts
      • 2.4.2.4.7. Scientists
      • 2.4.2.4.8. Doctors and Other Healthcare Providers
    • 2.4.2.5. Ethics and Integrity
      • 2.4.2.5.1. Research Ethics
      • 2.4.2.5.2. Data Integrity
  • 2.4.3. Analytical Tools and Databases
• 2.5. Robust Quality Control

3. MARKET DYNAMICS

• 3.1. Chapter Overview
• 3.2. Forecast Methodology
  • 3.2.1. Top-down Approach
  • 3.2.2. Bottom-up Approach
  • 3.2.3. Hybrid Approach
• 3.3. Market Assessment Framework
  • 3.3.1. Total Addressable Market (TAM)
  • 3.3.2. Serviceable Addressable Market (SAM)
  • 3.3.3. Serviceable Obtainable Market (SOM)
  • 3.3.4. Currently Acquired Market (CAM)
• 3.4. Forecasting Tools and Techniques
  • 3.4.1. Qualitative Forecasting
  • 3.4.2. Correlation
  • 3.4.3. Regression
  • 3.4.4. Extrapolation
  • 3.4.5. Convergence
  • 3.4.6. Sensitivity Analysis
  • 3.4.7. Scenario Planning
  • 3.4.8. Data Visualization
  • 3.4.9. Time Series Analysis
  • 3.4.10. Forecast Error Analysis
• 3.5. Key Considerations
  • 3.5.1. Demographics
  • 3.5.2. Government Regulations
  • 3.5.3. Reimbursement Scenarios
  • 3.5.4. Market Access
  • 3.5.5. Supply Chain
  • 3.5.6. Industry Consolidation
  • 3.5.7. Pandemic / Unforeseen Disruptions Impact
• 3.6. Limitations

4. MACRO-ECONOMIC INDICATORS

• 4.1. Chapter Overview
• 4.2. Market Dynamics
  • 4.2.1. Time Period
    • 4.2.1.1. Historical Trends
    • 4.2.1.2. Current and Forecasted Estimates
  • 4.2.2. Currency Coverage
    • 4.2.2.1. Major Currencies Affecting the Market
    • 4.2.2.2. Factors Affecting Currency Fluctuations on the Industry
    • 4.2.2.3. Impact of Currency Fluctuations on the Industry
  • 4.2.3. Foreign Currency Exchange Rate
    • 4.2.3.1. Impact of Foreign Exchange Rate Volatility on the Market
    • 4.2.3.2. Strategies for Mitigating Foreign Exchange Risk
  • 4.2.4. Recession
    • 4.2.4.1. Assessment of Current Economic Conditions and Potential Impact on the Market
    • 4.2.4.2. Historical Analysis of Past Recessions and Lessons Learnt
  • 4.2.5. Inflation
    • 4.2.5.1. Measurement and Analysis of Inflationary Pressures in the Economy
    • 4.2.5.2. Potential Impact of Inflation on the Market Evolution
  • 4.2.6. Interest Rates
    • 4.2.6.1. Interest Rates and Their Impact on the Market
    • 4.2.6.2. Strategies for Managing Interest Rate Risk
  • 4.2.7. Commodity Flow Analysis
    • 4.2.7.1. Type of Commodity
    • 4.2.7.2. Origins and Destinations
    • 4.2.7.3. Values and Weights
    • 4.2.7.4. Modes of Transportation
  • 4.2.8. Global Trade Dynamics
    • 4.2.8.1. Import Scenario
    • 4.2.8.2. Export Scenario
    • 4.2.8.3. Trade Policies
    • 4.2.8.4. Strategies for Mitigating the Risks Associated with Trade Barriers
    • 4.2.8.5. Impact of Trade Barriers on the Market
  • 4.2.9. War Impact Analysis
    • 4.2.9.1. Russian-Ukraine War
    • 4.2.9.2. Israel-Hamas War
  • 4.2.10. COVID Impact / Related Factors
    • 4.2.10.1. Global Economic Impact
    • 4.2.10.2. Industry-specific Impact
    • 4.2.10.3. Government Response and Stimulus Measures
    • 4.2.10.4. Future Outlook and Adaptation Strategies
  • 4.2.11. Other Indicators
    • 4.2.11.1. Fiscal Policy
    • 4.2.11.2. Consumer Spending
    • 4.2.11.3. Gross Domestic Product
    • 4.2.11.4. Employment
    • 4.2.11.5. Taxes
    • 4.2.11.6. Stock Market Performance
    • 4.2.11.7. Cross Border Dynamics
• 4.3. Conclusion

5. EXECUTIVE SUMMARY

• 5.1. Executive Summary: Market Landscape
• 5.2. Executive Summary: Market Trends
• 5.3. Executive Summary: Market Forecast and Opportunity Analysis

6. INTRODUCTION

• 6.1. Chapter Overview
• 6.2. Concept of an Antibody
• 6.3. Structure of an Antibody
• 6.4. Antibody Isotypes
• 6.5. Mechanism of Action of Antibodies
• 6.6. Types of Antibodies
  • 6.6.1. Monoclonal Antibodies
    • 6.6.1.1. Monoclonal Antibody-based Cancer Therapies
    • 6.6.1.2. Mechanism of Action of Monoclonal Antibodies
    • 6.6.1.3. Applications of Monoclonal Antibodies
  • 6.6.2. Bispecific Antibodies
    • 6.6.2.1. Bispecific Antibody Formats
    • 6.6.2.2. Mechanism of Action of Bispecific Antibodies
    • 6.6.2.3. Applications of Bispecific Antibodies
  • 6.6.3. Polyclonal Antibodies
    • 6.6.3.1. Applications of Polyclonal Antibodies
• 6.7. Overview of Contract Manufacturing
• 6.8. Need for Outsourcing in the Biopharmaceutical Industry
• 6.9. Advantages of Outsourcing Manufacturing Services

7. MARKET LANDSCAPE

• 7.1. Chapter Overview
• 7.2. Antibody Contract Manufacturers: Overall Market Landscape
  • 7.2.1. Analysis by Year of Establishment
  • 7.2.2. Analysis by Company Size
  • 7.2.3. Analysis by Location of Headquarters
  • 7.2.4. Analysis by Location of Antibody Contract Manufacturing Facilities
  • 7.2.5. Analysis by Scale of Operation
  • 7.2.6. Analysis by Type of Antibody Manufactured
  • 7.2.7. Analysis by Type of Expression System Used
  • 7.2.8. Analysis by Fill / Finish Services Offered

8. COMPANY COMPETITIVENESS ANALYSIS

• 8.1. Chapter Overview
• 8.2. Assumptions and Key Parameters
• 8.3. Methodology
• 8.4. Antibody Contract Manufacturers: Company Competitiveness Analysis
  • 8.4.1. Antibody Contract Manufacturers Based in North America (Peer Group I)
  • 8.4.2. Antibody Contract Manufacturers Based in Europe (Peer Group II)
  • 8.4.3. Antibody Contract Manufacturers Based in Asia-Pacific and Rest of the World (Peer Group III)

9. COMPANY PROFILES: PROMINENT PLAYERS

• 9.1. Chapter Overview
• 9.2. AGC Biologics
  • 9.2.1. Company Overview
  • 9.2.2. Antibody Contract Manufacturing Service Portfolio
  • 9.2.3. Recent Developments and Future Outlook
• Similar details are presented for other companies mentioned below (based on information in the public domain)
• 9.3. Aldevron
• 9.4. Axplora (formerly Novasep)
• 9.5. Emergent Biosolutions
• 9.6. Eurofins
• 9.7. FUJIFILM Diosynth Biotechnologies
• 9.8. KBI Biopharma
• 9.9. Lonza
• 9.10. Nitto Avecia Pharma Services
• 9.11. Pierre Fabre
• 9.12. Samsung Biologics
• 9.13. Synthon
• 9.14. Thermo Fisher Scientific

10. COMPANY PROFILES: EMERGING PLAYERS

• 10.1. Chapter Overview
• 10.2. ABL
  • 10.2.1. Company Overview
  • 10.2.2. Antibody Contract Manufacturing Service Portfolio
• Similar details are presented for other companies mentioned below (based on information in the public domain)
• 10.3. Absolute Antibody
• 10.4. Abzena
• 10.5. Allele Biotechnology & Pharmaceuticals
• 10.6. Alvotech
• 10.7. Antibody Production Services
• 10.8. Arabio
• 10.9. Bharat Serums and Vaccines
• 10.10. Boehringer Ingelheim
• 10.11. Glenmark Pharmaceuticals
• 10.12. MilliporeSigma
• 10.13. Siam Bioscience

11. CASE STUDY: COMPARISON OF SMALL AND LARGE MOLECULE (BIOLOGICS) DRUGS / THERAPIES

• 11.1. Chapter Overview
• 11.2. Small Molecules and Biologics
  • 11.2.1. Comparison of Strengths and Weakness of Small Molecules and Biologics
  • 11.2.2. Comparison of Key Characteristics of Small Molecules and Biologics
  • 11.2.3. Comparison of Manufacturing Processes of Small Molecules and Biologics
  • 11.2.4. Comparison of Key Manufacturing related Challenges

12. PARTNERSHIPS AND COLLABORATIONS

• 12.1. Chapter Overview
• 12.2. Partnerships Models
• 12.3. Antibody Contract Manufacturers: Partnerships and Collaborations
  • 12.3.1. Quarterly Trend of Partnerships
  • 12.3.2. Analysis by Type of Partnership
  • 12.3.3. Analysis by Quarterly Trend and Type of Partnership
  • 12.3.4. Most Active Players: Analysis by Number of Partnerships
  • 12.3.5. Analysis by Geography
    • 12.3.5.1. Local and International Agreements
    • 12.3.5.2. Intracontinental and Intercontinental Agreements

13. RECENT EXPANSIONS

• 13.1. Chapter Overview
• 13.2. Type of Expansions
• 13.3. Recent Expansions: Antibody Contract Manufacturing Organizations
  • 13.3.1. Quarterly Trend of Expansions
  • 13.3.2. Analysis by Type of Expansion
  • 13.3.3. Analysis by Quarterly Trend and Type of Expansion
  • 13.3.4. Analysis by Location of Facility (Region)
  • 13.3.5. Analysis by Location of Facility (Country)
  • 13.3.6. Analysis by Type of Expansion and Location of Facility (Region)
  • 13.3.7. Analysis of Amount Invested by Quarter of Expansion
  • 13.3.8. Analysis of Amount Invested by Type of Expansion
  • 13.3.9. Most Active Players: Analysis by Number of Expansions
  • 13.3.10. Most Active Players: Analysis by Amount Invested

14. CAPACITY ANALYSIS

• 14.1. Chapter Overview
• 14.2. Assumptions and Methodology
• 14.3. Antibody Contract Manufacturing: Global Installed Capacity
  • 14.3.1. Analysis by Company Size
  • 14.3.2. Analysis by Location of Manufacturing Facilities
  • 14.3.3. Analysis by Type of Expression System Used
• 14.4. Antibody Contract Manufacturing Capacity for Mammalian Expression Systems
  • 14.4.1. Analysis by Company Size
  • 14.4.2. Analysis by Location of Manufacturing Facilities
• 14.5. Antibody Contract Manufacturing Capacity for Microbial Expression Systems
  • 14.5.1. Analysis by Company Size
  • 14.5.2. Analysis by Location of Manufacturing Facilities
• 14.6. Concluding Remarks

15. DEMAND ANALYSIS

• 15.1. Chapter Overview
• 15.2. Assumptions and Methodology
• 15.3. Global Demand for Antibody Contract Manufacturing
  • 15.3.1. Demand for Antibody Contract Manufacturing: Distribution by Type of Antibody
  • 15.3.2. Demand for Antibody Contract Manufacturing: Distribution by Scale of Operation
  • 15.3.3. Demand for Antibody Contract Manufacturing: Distribution by Type of Manufacturer
  • 15.3.4. Demand for Antibody Contract Manufacturing: Distribution by Geographical Regions

16. MARKET IMPACT ANALYSIS: DRIVERS, RESTRAINTS, OPPORTUNITIES AND CHALLENGES

• 16.1. Chapter Overview
• 16.2. Market Drivers
• 16.3. Market Restraints
• 16.4. Market Opportunities
• 16.5. Market Challenges
• 16.6. Conclusion

17. GLOBAL ANTIBODY CONTRACT MANUFACTURING MARKET

• 17.1. Chapter Overview
• 17.2. Key Assumptions and Methodology
• 17.3. Global Antibody Contract Manufacturing Market: Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)
  • 17.3.1. Roots Analysis Perspective on Market Growth
  • 17.3.2 Scenario Analysis
    • 17.3.2.1. Conservative Scenario
    • 17.3.2.2. Optimistic Scenario
• 17.4. Key Market Segmentations

18. ANTIBODY CONTRACT MANUFACTURING MARKET, BY TYPE OF ANTIBODY MANUFCATURED

• 18.1. Chapter Overview
• 18.2. Key Assumptions and Methodology
• 18.3. Antibody Contract Manufacturing Market: Distribution by Type of Antibody Manufactured
  • 18.3.1. Antibody Contract Manufacturing Market for Monoclonal Antibodies: Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)
  • 18.3.2. Antibody Contract Manufacturing Market for Bispecific Antibodies: Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)
• 18.4. Data Triangulation and Validation

19. ANTIBODY CONTRACT MANUFACTURING MARKET, BY TYPE OF PRODUCT

• 19.1. Chapter Overview
• 19.2. Key Assumptions and Methodology
• 19.3. Antibody Contract Manufacturing Market: Distribution by Type of Product
  • 19.3.1. Antibody Contract Manufacturing Market for APIs: Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)
  • 19.3.2. Antibody Contract Manufacturing Market for FDFs: Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)
• 19.4. Data Triangulation and Validation

20. ANTIBODY CONTRACT MANUFACTURING MARKET, BY SCALE OF OPERATION

• 20.1. Chapter Overview
• 20.2. Key Assumptions and Methodology
• 20.3. Antibody Contract Manufacturing Market: Distribution by Scale of Operation
  • 20.3.1. Antibody Contract Manufacturing Market at Clinical Scale: Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)
  • 20.3.2. Antibody Contract Manufacturing Market at Commercial Scale: Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)
• 20.4. Data Triangulation and Validation

21. ANTIBODY CONTRACT MANUFACTURING MARKET, BY TYPE OF EXPRESSION SYSTEM USED

• 21.1. Chapter Overview
• 21.2. Key Assumptions and Methodology
• 21.3. Antibody Contract Manufacturing Market: Distribution by Type of Expression System Used
  • 21.3.1. Antibody Contract Manufacturing Market for Mammalian Expression System: Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)
  • 21.3.2. Antibody Contract Manufacturing Market for Microbial Expression System: Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)
• 21.4. Data Triangulation and Validation

22. ANTIBODY CONTRACT MANUFACTURING MARKET, BY THERAPEUTIC AREA

• 22.1. Chapter Overview
• 22.2. Key Assumptions and Methodology
• 22.3. Antibody Contract Manufacturing Market: Distribution by Therapeutic Area
  • 22.3.1. Antibody Contract Manufacturing Market for Oncological Disorders: Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)
  • 22.3.2. Antibody Contract Manufacturing Market for Cardiovascular Disorders: Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)
  • 22.3.3. Antibody Contract Manufacturing Market for Metabolic Disorders: Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)
  • 22.3.4. Antibody Contract Manufacturing Market for Infectious Diseases: Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)
  • 22.3.5. Antibody Contract Manufacturing Market for Autoimmune Disorders: Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)
  • 22.3.6. Antibody Contract Manufacturing Market for Neurological Disorders: Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)
  • 22.3.7. Antibody Contract Manufacturing Market for Genetic Disorders: Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)
  • 22.3.8. Antibody Contract Manufacturing Market for Other Disorders: Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)
• 22.4. Data Triangulation and Validation

23. ANTIBODY CONTRACT MANUFACTURING MARKET, BY SCALE OF OPERATION

• 23.1. Chapter Overview
• 23.2. Key Assumptions and Methodology
• 23.3. Antibody Contract Manufacturing Market: Distribution by Scale of Operation
  • 23.3.1. Antibody Contract Manufacturing Market at Clinical Scale: Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)
  • 23.3.2. Antibody Contract Manufacturing Market at Commercial Scale: Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)
• 23.4. Data Triangulation and Validation

24. ANTIBODY CONTRACT MANUFACTURING MARKET, BY GEOGRAPHICAL REGIONS

• 24.1. Chapter Overview
• 24.2. Key Assumptions and Methodology
• 24.3. Antibody Contract Manufacturing Market: Distribution by Key Geographical Regions
  • 24.3.1. Antibody Contract Manufacturing Market in North America: Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)
    • 24.3.1.1. Antibody Contract Manufacturing Market in the US: Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)
    • 24.3.1.2. Antibody Contract Manufacturing Market in Canada: Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)
    • 24.3.1.3. Antibody Contract Manufacturing Market in Puerto Rico: Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)
  • 24.3.2. Antibody Contract Manufacturing Market in Europe: Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)
    • 24.3.2.1. Antibody Contract Manufacturing Market in Germany: Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)
    • 24.3.2.2. Antibody Contract Manufacturing Market in the UK: Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)
    • 24.3.2.3. Antibody Contract Manufacturing Market in France: Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)
    • 24.3.2.4. Antibody Contract Manufacturing Market in Spain: Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)
    • 24.3.2.5. Antibody Contract Manufacturing Market in Italy: Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)
    • 24.3.2.6. Antibody Contract Manufacturing Market in Rest of Europe: Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)
  • 24.3.3. Antibody Contract Manufacturing Market in Asia-Pacific: Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)
    • 24.3.3.1. Antibody Contract Manufacturing Market in China: Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)
    • 24.3.3.2. Antibody Contract Manufacturing Market in South Korea: Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)
    • 24.3.3.3. Antibody Contract Manufacturing Market in Japan: Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)
    • 24.3.3.4. Antibody Contract Manufacturing Market in Singapore: Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)
    • 24.3.3.5. Antibody Contract Manufacturing Market in Rest of Asia-Pacific: Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)
  • 24.3.4. Antibody Contract Manufacturing Market in Rest of the World: Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)
    • 24.3.4.1. Antibody Contract Manufacturing Market in Israel: Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)
    • 24.3.4.2. Antibody Contract Manufacturing Market in Argentina: Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)
    • 24.3.4.3. Antibody Contract Manufacturing Market in Africa: Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)
• 24.4. Market Dynamics Assessment
  • 24.4.1. Market Movement Analysis
  • 24.4.2. Penetration-Growth (P-G) Matrix
• 24.5. Data Triangulation and Validation

25. SWOT ANALYSIS

• 25.1. Chapter Overview
• 25.2. Strengths
• 25.3. Weaknesses
• 25.4. Opportunities
• 25.5. Threats
• 25.6. Comparison of SWOT Factors
• 25.7. Concluding Remarks

26. FUTURE OF THE ANTIBODY CMO MARKET

• 26.1. Chapter Overview
• 26.2. Rise in Outsourcing Activity
• 26.3. Shift from One-time Contractual Engagements to Strategic Partnerships
• 26.4. Adoption of New and Innovative Technologies
  • 26.4.1. Single-use Bioreactors
  • 26.4.2. Bioprocess Automation
  • 26.4.3. Other Technologies
• 26.5. Growing Biosimilars Market to Contribute to the Growth of the Contract Services Segment
• 26.6. Capability Expansions by CMOs to become One Stop Shops
• 26.7. Offshoring Outsourcing Activities to Maximize Profits and Expand Existing Capacities
• 26.8. Challenges Faced by both Sponsors and Service Providers
• 26.9. Future Outlook

27. CONCLUDING REMARKS

28. EXECUTIVE INSIGHTS

29. APPENDIX 1: TABULATED DATA

30. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS